Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01273467 · ClinicalTrials.gov registry record · Phase 1
A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01273467 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 13 participants.
The verdict
NCT01273467, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of 42037788 (CNTO 0007) in patients who have suffered a stroke. The study is not designed to establish efficacy, although preliminary explorations will be conducted.
Interventions
- DRUG CNTO 0007 or placebo (Stage A)
- DRUG CNTO 0007 or placebo (Stage B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01273467
The ClinicalTrials.gov registry entry for NCT01273467 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CNTO 0007 or placebo (Stage A) is the first listed.
NCT01273467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01273467 about?
NCT01273467 is a clinical study titled "A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)". The purpose of this study is to evaluate the safety and tolerability of 42037788 (CNTO 0007) in patients who have suffered a stroke. The study is not designed to establish efficacy, although preliminary explorations will be conducted.
What is the current status of trial NCT01273467?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2010-12. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01273467?
The interventions under investigation include: CNTO 0007 or placebo (Stage A) (DRUG), CNTO 0007 or placebo (Stage B) (DRUG).
Who is sponsoring clinical trial NCT01273467?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.